Serina Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-19.2M | $-11.1M | $5.3M | $-10.5M | $-8.7M | $-10.9M | $-12.2M | $-7.5M |
| Depreciation & Amortization | $100.0K | $100.0K | $90.0K | — | — | $699.0K | $393.0K | $58.0K |
| Depreciation | — | — | — | — | — | $699.0K | $91.0K | $58.0K |
| Amortization | — | $100.0K | $131.0K | $132.0K | $131.0K | $132.0K | $558.0K | $477.0K |
| Stock-Based Compensation | — | $2.6M | $25.0K | $760.0K | $999.0K | $909.0K | $1.9M | $1.3M |
| Net Cash from Operating Activities | $-18.0M | $-17.1M | $-2.5M | $-5.9M | $-7.9M | $-7.8M | $-10.2M | $-8.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $59.0K | $22.0K | $504.0K | — | — | $20.0K | $641.0K | $21.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-59.0K | $-22.0K | $-504.0K | — | $666.0K | $-20.0K | $-361.0K | $1.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $17.4M | $13.2M | $10.1M | $6.0M | $7.2M | $6.0M | $6.3M | $6.0M |
| Net Change in Cash | $-616.0K | $-3.9M | $7.1M | $61.0K | $57.0K | $-1.9M | $-4.3M | $-668.0K |
| Free Cash Flow | $-18.0M | $-17.2M | $-3.0M | — | — | $-7.8M | $-10.8M | $-8.0M |